BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23555854)

  • 1. ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.
    Kacprzyk LA; Laible M; Andrasiuk T; Brase JC; Börno ST; Fälth M; Kuner R; Lehrach H; Schweiger MR; Sültmann H
    PLoS One; 2013; 8(3):e59976. PubMed ID: 23555854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.
    Boormans JL; Korsten H; Ziel-van der Made AJ; van Leenders GJ; de Vos CV; Jenster G; Trapman J
    Int J Cancer; 2013 Jul; 133(2):335-45. PubMed ID: 23319146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Germ Cell Gene TDRD1 as an ERG Target Gene and a Novel Prostate Cancer Biomarker.
    Xiao L; Lanz RB; Frolov A; Castro PD; Zhang Z; Dong B; Xue W; Jung SY; Lydon JP; Edwards DP; Mancini MA; Feng Q; Ittmann MM; He B
    Prostate; 2016 Oct; 76(14):1271-84. PubMed ID: 27272765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.
    Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; Henrique R; Jerónimo C; Sveen A; Mills IG; Skotheim RI; Lothe RA; Teixeira MR
    Neoplasia; 2012 Jul; 14(7):600-11. PubMed ID: 22904677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions.
    Cerveira N; Ribeiro FR; Peixoto A; Costa V; Henrique R; Jerónimo C; Teixeira MR
    Neoplasia; 2006 Oct; 8(10):826-32. PubMed ID: 17032499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
    Linn DE; Bronson RT; Li Z
    PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
    Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
    Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
    Perner S; Rupp NJ; Braun M; Rubin MA; Moch H; Dietel M; Wernert N; Jung K; Stephan C; Kristiansen G
    Int J Cancer; 2013 Feb; 132(4):807-12. PubMed ID: 22821757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.
    Singareddy R; Semaan L; Conley-Lacomb MK; St John J; Powell K; Iyer M; Smith D; Heilbrun LK; Shi D; Sakr W; Cher ML; Chinni SR
    Mol Cancer Res; 2013 Nov; 11(11):1349-61. PubMed ID: 23918819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delineation of TMPRSS2-ERG splice variants in prostate cancer.
    Hu Y; Dobi A; Sreenath T; Cook C; Tadase AY; Ravindranath L; Cullen J; Furusato B; Chen Y; Thangapazham RL; Mohamed A; Sun C; Sesterhenn IA; McLeod DG; Petrovics G; Srivastava S
    Clin Cancer Res; 2008 Aug; 14(15):4719-25. PubMed ID: 18676740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].
    Guo XQ; Gui YT; Cai ZM
    Yi Chuan; 2011 Feb; 33(2):117-22. PubMed ID: 21377967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.
    Dong J; Xiao L; Sheng L; Xu J; Sun ZQ
    Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.
    Casey OM; Fang L; Hynes PG; Abou-Kheir WG; Martin PL; Tillman HS; Petrovics G; Awwad HO; Ward Y; Lake R; Zhang L; Kelly K
    PLoS One; 2012; 7(7):e41668. PubMed ID: 22860005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer.
    Zoma M; Curti L; Shinde D; Albino D; Mitra A; Sgrignani J; Mapelli SN; Sandrini G; Civenni G; Merulla J; Chiorino G; Kunderfranco P; Cacciatore A; Kokanovic A; Rinaldi A; Cavalli A; Catapano CV; Carbone GM
    Nat Commun; 2021 Jul; 12(1):4147. PubMed ID: 34230470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer.
    Tolkach Y; Zarbl R; Bauer S; Ritter M; Ellinger J; Hauser S; Hüser L; Klauck SM; Altevogt P; Sültmann H; Dietrich D; Kristiansen G
    Am J Pathol; 2021 Apr; 191(4):618-630. PubMed ID: 33485866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers.
    Mani RS; Iyer MK; Cao Q; Brenner JC; Wang L; Ghosh A; Cao X; Lonigro RJ; Tomlins SA; Varambally S; Chinnaiyan AM
    Cancer Res; 2011 Aug; 71(16):5387-92. PubMed ID: 21676887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
    Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
    Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
    Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.
    Qu X; Randhawa G; Friedman C; O'Hara-Larrivee S; Kroeger K; Dumpit R; True L; Vakar-Lopez F; Porter C; Vessella R; Nelson P; Fang M
    Cancer Genet; 2013; 206(1-2):1-11. PubMed ID: 23352841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.